Article Text

Download PDFPDF
In vivo imaging with oligonucleotides for diagnosis and drug development
  1. B Tavitian
  1. Correspondence to:
    B Tavitian, Laboratoire d’imagerie de l’expression des génes, Service hospitalier Frédéric Joliot, CEA, INSERM 0103, Orsay, France Dr B Tavitian, CEA/INSERM 0103, 4 place Leclerc, 91401 Orsay cedex, France;
    tavitian{at}shfj.cea.fr

Abstract

Molecular imaging, the science that combines non-invasive in vivo imaging and molecular biology, has begun to use labelled oligonucleotides as radiotracers. Antisense oligonucleotides target gene expression at the RNA level, while aptamer oligonucleotides are designed to hit proteins of interest. Oligonucleotides for imaging cover a large range of applications, from the invention of new contrast agents for diagnosis to exquisite research tools for the development of new drugs.

  • in vivo imaging
  • positron emission tomography
  • oligonucleotide
  • antisense
  • aptamer
  • PET, positron emission tomography
  • SPECT, single photon emission computed tomography
  • FDG, 2′-deoxy-2′-fluoro-glucose
  • PKA, protein kinase A
  • LTR, long terminal repeat
  • HIV, human immunodeficiency virus
  • SELEX, sytematic evolution of ligands by exponential enrichment
  • PDGF, platelet derived growth factor
  • VEGF, vascular endothelial growth factor
  • siRNA, small interfering RNA
  • RNAi, RNA interference

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.